Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

Autophagy

Volumn 10, Issue 8, 2014, Pages 1380-1390

  Vogl, Dan T ^a   Stadtmauer, Edward A ^a   Tan, Kay See ^b   Heitjan, Daniel F ^b   Davis, Lisa E ^c   Pontiggia, Laura ^c   Rangwala, Reshma ^a,e   Piao, Shengfu ^a   Chang, Yunyoung C ^a,f   Scott, Emma C ^a   Paul, Thomas M ^a   Nichols, Charles W ^a   Porter, David L ^a   Kaplan, Janeen ^a   Mallon, Gayle ^a   Bradner, James E ^d   Amaravadi, Ravi K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f BOSTON UNIVERSITY   (United States)

Author keywords

Autophagy; Myeloma; Proteasome

Indexed keywords

ANTIBIOTIC AGENT; BORTEZOMIB; CYTOPLASM PROTEIN; HYDROXYCHLOROQUINE; LENALIDOMIDE; MAP1LC3A PROTEIN; SQSTM1 PROTEIN; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOPHAGY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CYTOPENIA; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPOTENSION; ILEUS; IMMUNOBLOTTING; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; MYELOMA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROTEIN DEGRADATION; STEADY STATE; STREPTOCOCCUS PNEUMONIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEAKNESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; RECURRENT DISEASE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; PYRAZINES; RECURRENCE;

EID: 84905494696     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.29264     Document Type: Article

References (45)

1. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98; PMID:15958804; http://dx.doi.org/10.1056/NEJMoa043445
2. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, et al.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906-17; PMID:18753647; http://dx.doi.org/10.1056/NEJMoa0801479
3. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009; 27:5023-30; PMID:19770386; http://dx.doi.org/10.1200/JCO.2008.17.7980
4. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113:6069-76; PMID:19380866; http://dx.doi.org/10.1182/blood-2009-01- 199679
5. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24:4867-74; PMID:17001068; http://dx.doi.org/10.1200/JCO.2006.07. 9665
6. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-75; PMID:15613697; http://dx.doi.org/10.1200/JCO.2005.03.108
7. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13:5291-4; PMID:17875757; http://dx.doi.org/10.1158/1078-0432.CCR-07-0871
8. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676-84; PMID:15613699; http://dx.doi.org/10.1200/JCO.2005.02.050
9. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10:6111-8; PMID:15447997; http://dx.doi.org/10.1158/1078-0432.CCR-04-0422
10. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol 2008; 26:2320-6; PMID:18467723; http://dx.doi.org/10.1200/JCO.2007.14.0152
11. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:5025-33; PMID:17075122; http://dx.doi.org/10.1200/JCO.2006.06.1853
12. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 2005; 16:1654-61; PMID:16085692; http://dx.doi.org/10.1093/annonc/mdi324
13. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113:3040-9; PMID:19164601; http://dx.doi.org/10.1182/ blood-2008-08-172734
14. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306:990-5; PMID:15528435; http://dx.doi.org/10.1126/ science.1099993
15. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115:2679-88; PMID:16200202; http://dx.doi.org/10.1172/JCI26390
16. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447:859-63; PMID:17568747; http://dx.doi.org/10.1038/nature05853
17. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005; 280:40282-92; PMID:16192271; http://dx.doi.org/10.1074/jbc.M508786200
18. Wu WK, Cho CH, Lee CW, Wu YC, Yu L, Li ZJ, Wong CC, Li HT, Zhang L, Ren SX, et al. Macroautophagy and ERK phosphorylation counter-act the antiproliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy 2010; 6:228-38; PMID:20087064; http://dx.doi.org/10.4161/auto.6.2. 11042
19. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, Yin XM. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007; 171:513-24; PMID:17620365; http://dx.doi.org/10.2353/ajpath.2007.070188
20. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005; 102:8567-72; PMID:15937109; http://dx.doi.org/10.1073/pnas.0503221102
21. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117:326-36; PMID:17235397; http://dx.doi.org/10.1172/JCI28833
22. Poole B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol 1981; 90:665-9; PMID:6169733; http://dx.doi.org/10.1083/jcb.90.3.665
23. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17:654-66; PMID:21325294; http://dx.doi.org/10.1158/1078-0432.CCR-10-2634
24. Hui B, Shi YH, Ding ZB, Zhou J, Gu CY, Peng YF, Yang H, Liu WR, Shi GM, Fan J. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer 2012; 118:5560-71; PMID:22517429; http://dx.doi.org/10.1002/cncr.27586
25. Jia L, Gopinathan G, Sukumar JT, Gribben JG. Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells. PLoS One 2012; 7:e32584; PMID:22393418; http://dx.doi.org/10.1371/journal.pone.0032584
26. Yao F, Wang G, Wei W, Tu Y, Tong H, Sun S. An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells. Mol Med Rep 2012; 5:84-8; PMID:21931937
27. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 2009; 69:4415-23; PMID:19417138; http://dx.doi.org/10.1158/0008-5472.CAN-08-2839
28. Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, Naito M, Itoh M, Tomoda A. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol 2011; 38:643-54; PMID:21174067
29. Shen, John Paul Y. C., Divakaran S, Ponduru S, Vogl DT, Amaravadi RK, Bradner JE. The rationale for combined proteasome and autophagy inhibition in multiple myeloma established using novel translational platforms. American Society of Hematology 2008; 112:2755
30. Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemother Pharmacol 2013; 71:1567-76; PMID:23572175; http://dx.doi.org/10.1007/s00280-013- 2156-3
31. Ding WX, Ni HM, Gao W, Chen X, Kang JH, Stolz DB, Liu J, Yin XM. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 2009; 8:2036-45; PMID:19584239; http://dx.doi.org/10.1158/1535-7163.MCT-08-1169
32. Hui B, Shi YH, Ding ZB, Zhou J, Gu CY, Peng YF, Yang H, Liu WR, Shi GM, Fan J. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer 2012; 118:5560-71; PMID:22517429; http://dx.doi.org/10.1002/cncr.27586
33. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, et al. Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 1403-14; PMID:24991835; http://dx.doi.org/10.4161/auto.29231
34. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 1359-68; PMID:24991840; http://dx.doi.org/10.4161/auto.28984
35. Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988; 26:303-13; PMID:3179169; http://dx.doi.org/10.1111/j.1365-2125.1988.tb05281.x
36. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 1369-79; PMID:24991839; http://dx.doi.org/10.4161/ auto.29118
37. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 2014; 1415-25; PMID:24991836; http://dx.doi.org/10.4161/auto.29165
38. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, Lynch JP, Uehara T, Sepulveda AR, Davis LE, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A 2012; 109:8253-8; PMID:22566612; http://dx.doi.org/10.1073/pnas.1118193109
39. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr., Pal A, Bornmann WG, Chiao PJ, Huang P, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66:3773-81; PMID:16585204; http://dx.doi.org/10.1158/0008-5472. CAN-05-2961
40. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013; 14:1129-40; PMID:24055414; http://dx.doi.org/10.1016/S1470-2045(13)70398-X
41. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122:2331-7; PMID:23950178; http://dx.doi.org/10.1182/blood-2013-01-481325
42. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004; 11:448-57; PMID:14713959; http://dx.doi.org/10.1038/sj.cdd. 4401359
43. Rangwala R, Chang YC, Hu J, Algazy K, Evans T, Fecher L, Schuchter L, Torigian DA, Panosian J, Troxel A, et al. Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 1391-1402; PMID:24991838; http://dx.doi.org/10.4161/auto.29119
44. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al.; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467-73; PMID:16855634; http://dx.doi.org/10.1038/sj.leu. 2404284
45. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3-9; PMID:18971951; http://dx.doi.org/10.1038/leu.2008.291